Literature DB >> 2824463

Stimulation and inhibition of cAMP accumulation by glucagon in canine hepatocytes.

T Grady1, M Fickova, H S Tager, D Trivedi, V J Hruby.   

Abstract

We have examined, by use of isolated canine hepatocytes and selected hormone analogs, the mechanisms by which glucagon modifies the accumulation of cellular cAMP. Low concentrations of glucagon (less than or equal to 3 nM) enhanced the accumulation of hepatocyte cAMP, whereas higher concentrations of the hormone diminished the effectiveness of lower ones. This biphasic concentration dependence was observed as well for some glucagon analogs, but not for others, and was apparent for cells incubated in the presence or absence of theophylline. Glucagon at high concentrations (greater than or equal to 10 nM) also inhibited the accumulation of cAMP induced by isoproterenol. The inhibitory effect of glucagon in both of these systems was reversed or attenuated by cell incubations involving the use of pertussis toxin (islet-activating protein) or a peptide antagonist of the glucagon-adenylyl cyclase system. We conclude that (a) glucagon, through its interaction with high and low affinity binding sites, can either stimulate or inhibit the production of hepatocyte cAMP; (b) the inhibitory action of the hormone appears to arise from interactions of ligand with a subset of these binding sites and to require structural characteristics in addition to those that determine receptor binding affinity per se; and (c) the glucagon and adrenergic systems involved in stimulating cAMP accumulation are linked, at least with regard to the negative effect induced by high concentrations of glucagon.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824463

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Cell cultures of neuroblasts from rat olfactory epithelium that show odorant responses.

Authors:  H G Coon; F Curcio; K Sakaguchi; M L Brandi; R D Swerdlow
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

Review 2.  Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.

Authors:  Victor J Hruby; Minying Cai
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

3.  Mechanism of action of des-His1-[Glu9]glucagon amide, a peptide antagonist of the glucagon receptor system.

Authors:  S R Post; P G Rubinstein; H S Tager
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

4.  Neuropeptide Y modulates ATP-induced increases in internal calcium via the adenylate cyclase/protein kinase A system in a human neuroblastoma cell line.

Authors:  V Soares Lemos; B Bucher; K Takeda
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

5.  Effect of adrenergic agonists and antagonists on alanine amino transferase, fructose-1:6-bisphosphatase and glucose production in hepatocytes.

Authors:  N A Begum; A G Datta
Journal:  Mol Cell Biochem       Date:  1992-08-18       Impact factor: 3.396

6.  Modulation of Glucagon Receptor Pharmacology by Receptor Activity-modifying Protein-2 (RAMP2).

Authors:  Cathryn Weston; Jing Lu; Naichang Li; Kerry Barkan; Gareth O Richards; David J Roberts; Timothy M Skerry; David Poyner; Meenakshi Pardamwar; Christopher A Reynolds; Simon J Dowell; Gary B Willars; Graham Ladds
Journal:  J Biol Chem       Date:  2015-07-21       Impact factor: 5.157

7.  Neuromedin U uses Gαi2 and Gαo to suppress glucose-stimulated Ca2+ signaling and insulin secretion in pancreatic β cells.

Authors:  Weidong Zhang; Hideyuki Sakoda; Yuki Nakazato; Md Nurul Islam; François Pattou; Julie Kerr-Conte; Masamitsu Nakazato
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.